Literature DB >> 19324982

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder.

M Bonnan1, R Valentino, S Olindo, H Mehdaoui, D Smadja, P Cabre.   

Abstract

BACKGROUND: Plasma exchange (PE) is increasingly undertaken in diseases involving humoral factors and is proven to be beneficial in acute demyelinating diseases. Spinal attacks in relapsing neuromyelitis optica (NMO) and in extensive transverse myelitis (ETM) - a truncated form of NMO with spinal involvement - are usually devastating.
OBJECTIVE: We retrospectively studied the outcome of PE-treated versus steroid-only treated spinal attacks in relapsing NMO and ETM.
METHODS: We included 96 severe spinal attacks in 43 Afro-Caribbean patients. PE was given as an add-on therapy in 29 attacks. Expanded disability status score (EDSS) was obtained before attack, during the acute and residual stage. We defined the DeltaEDSS as the rise from basal to residual EDSS.
RESULTS: The DeltaEDSS was found to be lower in the PE-treated group (1.2 +/- 1.6 vs 2.6 +/- 2.3; P < 0.01). A low basal impairment is associated with a better outcome. Improvement was obtained in both NMO-IgG negative and positive NMO attacks. Minor adverse events manifested in seven PE sessions (24%).
CONCLUSION: PE appears to be a safe add-on therapy that may be employed early in severe spinal attacks in the NMO spectrum disorders in order to maximize improvement rate. PE efficiency is independent of NMO-IgG positivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324982     DOI: 10.1177/1352458508100837

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  54 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

2.  Plasmapheresis: are bigger studies necessarily better?

Authors:  Brian Weinshenker
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

3.  Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.

Authors:  Anil Tombak; Mehmet Ali Uçar; Aydan Akdeniz; Arda Yilmaz; Hakan Kaleagası; Mehmet Ali Sungur; Eyup Naci Tiftik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-22       Impact factor: 0.900

Review 4.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

Review 5.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

6.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

7.  Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.

Authors:  Hesham Abboud; Alex Petrak; Maureen Mealy; Sarana Sasidharan; Laila Siddique; Michael Levy
Journal:  Mult Scler       Date:  2015-04-28       Impact factor: 6.312

8.  Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

Authors:  Romain Marignier; Pascale Giraudon; Sandra Vukusic; Christian Confavreux; Jérôme Honnorat
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

9.  Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.

Authors:  Sotaro Mori; Takuji Kurimoto; Kaori Ueda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2018-05-25       Impact factor: 2.447

Review 10.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.